Vivos Therapeutics (VVOS) Institutional Ownership $4.20 -0.40 (-8.70%) Closing price 04:00 PM EasternExtended Trading$4.22 +0.02 (+0.48%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Vivos Therapeutics (NASDAQ:VVOS)CurrentInstitutional OwnershipPercentage26.35%Number ofInstitutional Buyers(last 12 months)7TotalInstitutional Inflows(last 12 months)$1.64MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$75.14K Get VVOS Insider Trade Alerts Want to know when executives and insiders are buying or selling Vivos Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data VVOS Institutional Buying and Selling by Quarter Vivos Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/19/2025 B. Riley Wealth Advisors Inc.69,531$220K0.0%N/A1.180% 8/12/2025 XTX Topco Ltd20,528$65K0.0%N/A0.349% 5/1/2025 Cutter & CO Brokerage Inc.49,100$140K0.0%+28.9%0.834% 4/22/2025 EWA LLC10,464$30K0.0%N/A0.178% 2/17/2025 Anson Funds Management LP242,583$1.04M0.1%N/A4.119% 2/12/2025 Geode Capital Management LLC44,827$192K0.0%+55.6%0.761% 2/10/2025 Commonwealth Equity Services LLC26,000$112K0.0%+23.8%0.441% 2/4/2025 Cutter & CO Brokerage Inc.38,100$163K0.0%N/A0.647% 10/24/2024 Strategic Wealth Investment Group LLC100,000$252K0.0%-22.4%2.096% 2/13/2024 Armistice Capital LLC57,000$709K0.0%N/A4.286% Get the Latest News and Ratings for VVOS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/16/2024 Strategic Wealth Investment Group LLC128,789$1.60M0.2%-96.0%9.683% 4/24/2023 Strategic Wealth Investment Group LLC3,219,705$1.10M0.2%N/A12.874% 4/20/2023 Strategic Wealth Investment Group LLC232,737$1.10M0.2%N/A0.931% 4/18/2023 Godsey & Gibb Inc.92,999$32K0.0%N/A0.372% 2/10/2023 Bard Associates Inc.201,704$81K0.0%-6.9%0.806% 11/16/2022 SeaCrest Wealth Management LLC40,000$26K0.0%N/A0.174% 11/9/2022 Boston Partners78,454$51K0.0%-36.8%0.341% 11/4/2022 Russell Investments Group Ltd.365,901$236K0.0%-11.1%1.590% 10/24/2022 Perkins Capital Management Inc.56,500$37K0.0%-65.5%0.246% 7/29/2022 Perkins Capital Management Inc.163,800$211K0.2%+9.2%0.712% 7/29/2022 Russell Investments Group Ltd.411,589$530K0.0%-3.1%1.789% 5/10/2022 Boston Partners137,354$368K0.0%+27.2%0.597% 5/5/2022 Russell Investments Group Ltd.424,801$1.14M0.0%+39.2%1.846% 5/2/2022 National Asset Management Inc.98,574$265K0.0%+24.4%0.428% 4/20/2022 Perkins Capital Management Inc.150,050$402K0.3%+10.3%0.652% 4/12/2022 Griffin Asset Management Inc.70,200$188K0.0%+63.3%0.305% 2/10/2022 Perkins Capital Management Inc.136,050$306K0.2%-7.1%0.591% 2/4/2022 Boston Partners108,015$243K0.0%+131.5%0.469% 2/3/2022 Cambridge Investment Research Advisors Inc.19,200$43K0.0%+60.0%0.083% 1/28/2022 Griffin Asset Management Inc.43,000$97K0.0%-13.1%0.187% 1/28/2022 National Asset Management Inc.79,270$179K0.0%+55.5%0.344% 1/21/2022 Russell Investments Group Ltd.305,096$684K0.0%+554.0%1.326% 11/16/2021 Schonfeld Strategic Advisors LLC34,443$139K0.0%N/A0.151% 11/16/2021 National Asset Management Inc.50,987$206K0.0%+46.9%0.224% 11/16/2021 Two Sigma Investments LP157,324$636K0.0%N/A0.690% 11/12/2021 WMS Partners LLC12,167$49K0.0%-27.0%0.053% 11/12/2021 Blueshift Asset Management LLC18,826$76K0.0%N/A0.083% 11/9/2021BlackRock Inc.48,905$198K0.0%+255.8%0.214% 11/8/2021Avalon Investment & Advisory329,322$1.33M0.0%+73.6%1.444% 11/8/2021 Russell Investments Group Ltd.46,651$188K0.0%N/A0.205% Trump’s betrayal exposed (Ad)Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.Millions of Americans are about to be wiped out, while others could make a fortune… click here to ma11/5/2021 Boston Partners46,651$188K0.0%N/A0.205% 11/2/2021 Cambridge Investment Research Advisors Inc.12,000$48K0.0%-68.0%0.053% 10/25/2021 Perkins Capital Management Inc.146,500$592K0.4%-9.8%0.642% 8/17/2021 Walleye Capital LLC150,000$743K0.0%N/A0.658% 8/16/2021 WMS Partners LLC16,667$153K0.0%N/A0.073% 8/16/2021 Archon Capital Management LLC215,000$1.06M0.1%N/A0.942% 8/13/2021 Renaissance Technologies LLC19,200$95K0.0%N/A0.084% 8/13/2021 Northern Trust Corp11,483$57K0.0%N/A0.050% 8/13/2021 Geode Capital Management LLC47,661$235K0.0%+285.0%0.209% 8/13/2021 Vanguard Group Inc.383,891$1.90M0.0%N/A1.683% 8/12/2021 Bard Associates Inc.215,500$1.07M0.3%N/A0.945% 8/11/2021Millrace Asset Group Inc.93,993$465K0.2%N/A0.412% 8/10/2021 National Asset Management Inc.34,718$172K0.0%+21.9%0.152% 8/10/2021 Cambridge Investment Research Advisors Inc.37,551$186K0.0%N/A0.165% 5/18/2021 Millennium Management LLC78,898$524K0.0%-5.4%0.346% (Data available from 1/1/2016 forward) VVOS Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of VVOS shares? During the previous two years, 9 institutional investors and hedge funds held shares of Vivos Therapeutics. The most heavily invested institutionals were Anson Funds Management LP ($1.04M), Armistice Capital LLC ($709K), Strategic Wealth Investment Group LLC ($252K), B. Riley Wealth Advisors Inc. ($220K), Geode Capital Management LLC ($192K), Cutter & CO Brokerage Inc. ($140K), and Commonwealth Equity Services LLC ($112K).Learn more on Vivos Therapeutics' institutional investors. What percentage of Vivos Therapeutics' stock is owned by institutional investors? 26.35% of Vivos Therapeutics' stock is owned by institutional investors. Learn more on VVOS's institutional investor holdings. Which institutional investors have been buying Vivos Therapeutics' stock? The following institutional investors have purchased Vivos Therapeutics' stock in the last 24 months: Anson Funds Management LP ($242.58K), B. Riley Wealth Advisors Inc. ($69.53K), Armistice Capital LLC ($57K), Cutter & CO Brokerage Inc. ($49.10K), XTX Topco Ltd ($20.53K), Geode Capital Management LLC ($16.03K), and EWA LLC ($10.46K). How much institutional buying is happening at Vivos Therapeutics? Institutional investors have bought a total of 413,231 shares in the last 24 months. This purchase volume represents approximately $1.64M in transactions. Which of Vivos Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Vivos Therapeutics stock in the last 24 months: Strategic Wealth Investment Group LLC ($28.79K). How much institutional selling is happening at Vivos Therapeutics? Institutional investors have sold a total of 28,789 shares in the last 24 months. This volume of shares sold represents approximately $75.14K in transactions. Related Companies Fonar Institutional Ownership Hyperfine Institutional Ownership enVVeno Medical Institutional Ownership Apyx Medical Institutional Ownership Vivani Medical Institutional Ownership Nutriband Institutional Ownership TELA Bio Institutional Ownership Pulmonx Institutional Ownership Safe Pro Group Institutional Ownership Cytosorbents Institutional Ownership This page (NASDAQ:VVOS) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access